ALSO NOTED: MedImmune acquisition could pay dividends; Sun challenges J&J patent;

> Analysts say AstraZeneca's buyout of MedImmune could pay extra dividends as health officials expand their recommendations for an flu jab to all children between the ages of six months and 18. Report

> Sun Pharmaceuticals is challenging Johnson & Johnson's patent on the schizophrenia med Risperdal in the Mumbai, India, patent office. Report

> Pfizer has launched its stop-smoking med in India under the name Champix. Report

> AstraZeneca says it will push ahead with late-stage studies of Recentin for colorectal cancer after shelving plans for a Phase III in non-small cell lung cancer due to toxicity concerns. Report

> The nation's top biotech analysts have looked over the field of presidential candidates and announced a big winner: stem cell companies. Report

> GSK's secret vaccine adjuvant is drawing attention. Report

> Maryland lawmakers are considering a bill that could pump between $5 million and $10 million next year into a program to support the development of nano-biotech companies. Report

> The CDC has greatly expanded the population of people it's recommending for an annual flu shot, saying everyone aged six months to 18 should get the an annual jab. Report

And Finally… An MIT student found a way to make antibiotics more effective, winning a $30,000 prize for his efforts. Report

Suggested Articles

It’s final: England won’t be covering AZ’s quick-selling Tagrisso in previously untreated non-small cell lung cancer patients with EGFR mutatations.

Top J&J meds have managed to hang onto market share in the face of new generics and biosims, but the drugmaker expects the pain to continue in 2020.

Lonza’s search for a new CEO is expected to be wrapped up this year as the CDMO homes in on a list of veterans from outside the company.